Investor Relations


Investor Relations


• 24 October, 2019 – Swedencare AB (publ) – Interim Report Q3 2019 (1 July – 30 September 2019)
• 13 February, 2020 – Swedencare AB (publ) – Yearend Report Q4 2019 (1 October – 31 December 2019)
• 23 April, 2020 – Swedencare AB (publ) – Interim Report Q1 2020 (1 January – 31 March 2020)
• 24 July, 2020 – Swedencare AB (publ) – Half Year Report Q2 2020 (1 April – 30 June 2020)


CEO Comments

“Continued strong sales development
with the US and Asia in the lead”

HÅKAN LAGERBERG, CEO – SWEDENCARE AB (PUBL)


SALES AND EARNINGS (Q2/2019):

Net SalesQ2 2019

30 376

KSEK ( 18%)

EBITQ2 2019

8 657

KSEK ( 17%)

Share this information:

Company Information


“Continued strong sales development with the US and Asia in the lead”

SECOND QUARTER: April 1st – June 30th 2019

(Numbers in parentheses refer to outcomes during the corresponding period of the previous year.)

•  Net revenue amounted to 30 376 KSEK (25 669 KSEK), a increase of 18%.
•  Organic, currency-adjusted growth amounted to 15% .
•  Operating profit begore depreciation (EBITDA) amounted to 9 158 KSEK (7 125 KSEK),
corresponding to an increase of 29% corresponding to an EBITDA-margin of 30,1% (27,7%).
•  Operating profit after depreciation (EBIT) amounted to 8 657 KSEK (7 420 KSEK),
corresponding to an increase of 17% corresponding to an EBIT-margin of 28,4% (28,8%).
•  Profit after tax amounted to 6 809 KSEK (5 815 KSEK).
•  Profit per share, based on 15 770 622 shares 0,43 SEK (0.37 SEK).
•  As of June 30th 2019 cash amounted to 39 076 KSEK (24 972 KSEK).

FIRST 6-MONTHS: Jan 1st – Jun 30th 2019

(Numbers in parentheses refer to outcomes during the corresponding period of the previous year.)

•  Net revenue amounted to 60 926 TSEK (47 353 TSEK), a increase of 29%.
•  Organic, currency-adjusted growth amounted to 23% .
•  Operating profit before depreciation (EBITDA) amounted to 19 974 TSEK (13 184 TSEK),
corresponding to an increase of 52% corresponding to an EBITDA-margin of 32,7% (27,7%).
•  Operating profit after depreciation (EBIT) amounted to 19 335 TSEK (13 432 TSEK),
corresponding to an increase of 44% corresponding to an EBIT-margin of 31,7% (28,3%).
•  Profit after tax amounted to 15 317 TSEK (10 616 TSEK).
•  Earnings per share calculated on 15 770 622 shares 0,97 SEK (0.67 SEK).
•  Cash flow from operating activities amounted to 15 769 TSEK (7 763 TSEK).
•  Foreign exchange gains amounted to 797 TSEK.

Significant events during the second quarter:

•  DNCA – Invest Beyond Global Leaders and Invest Norden Europe, which is an international institution,
becomes a new major shareholder of Swedencare AB (publ).

Significant events after the second quarter:

•  There are no significant events after the end of the second quarter to report.

Words from the CEO:

Solid development during Q2 – continued good growth and despite increased investments, a good margin.

The second quarter net sales of 30,4 MSEK represents an increase of 18% compared to Q2 2018. The result developed even better and we showed an EBITDA of 9,2 MSEK, an increase of 29% compared to 2018. The EBITDA margin was 30.1%, just above our 30% profit target.

Most markets showed continued good development in the aftermath of a very strong Q1. North America continues to deliver, this time with a 54% increase in sales, despite the fact that it was not until June we were able to deliver the first batch of the now US-made Dental Bites. Having noted the sale of Dental Bites for the first time this year, I look forward to being able to meet the demand of the product in the US market and to be able to report it in future reports. Furthermore, it was first in June that we caught up with our back orders for Dental Bones for which the demand has been very high. We have made investments to be able to double the production of Dental Bones, something we expect to achieve during early autumn. We have also expanded our sales force with a very experienced person in Paul St. Germain responsible for the northeastern US and eastern Canada. Paul joined us in May and has already delivered.

The UK was good but not quite as good as the strong Q1 which was somewhat affected by the fact that some of our customers ordered unusually much considering the risk of a hard Brexit. Despite moving Spain into a separate company, Southern Europe is increasing its turnover and this to a considerably higher profit margin. France, Portugal and Greece are the countries mainly moving forward. Among other things, a Dental Bones campaign was conducted in Greece that sold out in one month to compare with the plan that it would last for three months.

Spain will be a much better market for us in the future, with the establishment of our own subsidiary. We have now signed up regional distributors covering the whole country and we have already been able to deliver small orders to some. However, it was only on July 1st as we got back all the sales rights in Spain, hence Q2 mostly consisted of establishing contacts, logistics and marketing. During Q2, the start up of our own sales company in Spain affected the result by approx 660 KSEK, but now we are well prepared to start showing black figures in the second half. Our production facility in Ireland takes over more and more of our ProDen PlaqueOff® production and in order to switch up, we have carried out a GMP inspection and hope to obtain an approval during the year. We also work to get our factory approved for Chinese exports, which in that case would open up many business opportunities for our product family NutriScience. It is an extensive process, but both we and our partner in China are working hard to get an approval.

Regarding the rest of the world, it was mainly Asia that was strong in the quarter, while Russia and the Czech Republic increased a lot percentage wise. China, which had a very strong Q2, increased its purchases from us somewhat while their sales increased by over 80%. This means that during the second half of the year we will see higher deliveries from us as our partner has now optimized their inventory. Shipments to Korea and Japan increased by over 70% in Q2 and it will be interesting to follow up the introduction of our cat version of ProDen PlaqueOff® powder in Japan which will be launched in Q3.

Last year, we had major deliveries to Australia during the first half of the year, while the completed first
half of 2019 has proceeded according to plan without follow-up orders. Our relaunch continues to do well, something I saw myself in May when visiting our Australian partners. During the second half of the year, we look forward to new orders to deliver, while our partner is working to expand the product range from us.

I am extremely pleased with the development of the first half of 2019 and I feel confident that the second
half will mean a continued strong development as we have a very positive momentum in our most important markets and many new business projects that will have a positive impact on us. For myself spring has also been busy with many investor relations. Our high growth and our good results have attracted the interest of many new, mainly international stakeholders. We therefore see that our international sales network now also gets a counterpart in an increasingly international ownership.

In meetings with analysts and shareholders, we are often asked how we look at supplementing organic growth with acquisitions. Of course, if we make an acquisition, this will be communicated in the usual order, but I can confirm that we are still actively working on our acquisition strategy. During the autumn, the Board intends to communicate the company’s new financial goals and in the process to establish these, a review of potential acquisitions which would contribute positively to our product offering, our market presence and to the company’s growth and earnings development will be completed.

I hope you all have a great summer, I myself look forward to a few weeks off before it is time to go to the US for SuperZoo in mid-August where we will launch our new Mini Dental Bones – one of many exciting business development projects this fall and winter!

Thank you,
Håkan Lagerberg, CEO
Malmö, July 26th 2019

Read the half year report in its entirety here:    (Print)    (Screen)

FOR FURTHER INFORMATION:
Håkan Lagerberg, CEO
Tel: +46 (0)735-170 170, E-mail: hakan.lagerberg@swedencare.se

Jenny Graflind, CFO
Tel: +46 (0)739-448 554, E-mail: jenny.graflind@swedencare.se

Swedencare develop, produce, market and sell premium products on the global and fastgrowing market within animal healthcare for cats, dogs and horses. The product groups ProDen PlaqueOff and NutriScience are represented on approximately fifty markets in all parts of the world, including the headquarter in Malmö, six subsidiaries in the Nordics, United States, France, Spain, Great Britain and Ireland and through an external distribution network. Swedencare’s sales have increased significantly over the last few years with strong margins and results. The board of directors and the management have a wide and extensive experience of international marketing and sales.

Denna information är sådan information som Swedencare AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning och lagen om värdepappersmarknaden. Informationen lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 26 juli 2019 kl. 08.30 CET.

Calendar Period: 2019/2020
Date Event
2 September, 2019 Swedencare AB (publ) participates at Introduce Investor Days in Stockholm, September 2.
Please click here for more information and registration.
24 October, 2019 Interim Report Q3 2019 (1 July – 30 September 2019)
13 February, 2020 Yearend Report Q4 2019 (1 October – 31 December 2019)
23 April, 2020 Interim Report Q1 2020 (1 January – 31 March 2020)
24 July, 2020 Half Year Report Q2 2020 (1 April – 30 June 2020)
Links to quarterly reports, annual reports
and prospectus for Swedencare AB (publ).

Below are listed the largest shareholders in
Swedencare AB (publ) as of 30/06 2019.
Name Shares Shareholding (%)
Håkan Svanberg & Co Health Care AB 4,690,982 29.75%
Mastan AB (Håkan Lagerberg via company) 1,590,362 10.08%
JCC Group Invest Sweden AB (Johan Bergdahl via company) 1,552,351 9.84%
DNCA Investments – NEW 1 234,500 7,83%
AMF Aktiefond Småbolag 755,000 4,79%
SHB Fonder 500,000 3.17%
Aktia Nordic Micro Cap 496,614 3.15%
Nordnet Pensionsförsäkring AB 361,929 2.29%
Martin Shimko – MD Swedencare USA 300,000 1.90%
Investment AB Spiltan 300,000 1.90%
Avanza 229,156 1.45%
ML, Pierce Fenner & Smith Inc. 222,173 1,41%
JP Morgan, UK – NEW 215,565 1.37%
Hans Persson – MD Swedencare France 199,751 1,27%
Enter Småbolagsfond 195,000 1,24%
Grandeur, Fund BBHBOS 194,678 1.23%
Tedcap AB (Thomas Eklund via company) 190,000 1,20%
Jonas Pålsson 172,736 1,10%
Aktia Secura 160,000 1.01%
COGEFI – NEW 130,000 0.82%
Per Malmström Consulting AB 123,000 0,78%
Others 1,956,825 12.41%
Total 15,770,622 100%
Free Float* 7,623,927 48,34%

Holdings include related parties
* Shares not owned by board members, their affiliates, or shareholders with more than 10%

For the current price and other share-related information,
please refer to Nasdaq First North.

First North is an alternative marketplace operated by OMX Nordic Exchange Stockholm. Companies whose shares are traded on First North are not obliged to comply with the same rules as listed companies, but a less extensive regulatory framework applied to preferably smaller companies and growth companies. A placement in a company whose shares are traded on First North may therefore be more risky than a placement in a listed company. All companies whose shares are traded on First North have a Certified Adviser that oversees the company’s compliance with First North’s regulatory framework for providing information to the market and investors. Certified Adviser reviews companies whose shares are to be traded on First North. OMX Nordic Exchange Stockholm accepts the application for admission to such trade.

   Click here for our current share price at Nasdaq First North.
ISIN-code Shortname
SE0008294078 SECARE
Certified Adviser: FNCA Sweden AB – phone: +46(8) 528 00 399 – Email: info@fnca.se – Address: Box 5807, 102 48 Stockholm, Sweden
Links to public presentations
of Swedencare AB (publ).
Date Description Download Video
15 March, 2019 Swedencare AB (publ) – Sit-down interview with CEO Håkan Lagerberg (Q4 2018)
15 March, 2019 Swedencare AB (publ) – Company presentation with CEO Håkan Lagerberg (Q4 2018)
4 September, 2018 Swedencare AB (publ) – Sit-down interview with CEO Håkan Lagerberg (Q2 2018)
4 September, 2018 Swedencare AB (publ) – Company presentation with CEO Håkan Lagerberg (Q2 2018)
26 April, 2018 Swedencare AB (publ) – Interview with CEO Håkan Lagerberg (Q1 2018)
20 April, 2018 Swedencare AB (publ) – Remiums analys till institutioner, köp riktkurs 44 SEK
11 September, 2017 Swedencare AB (publ) – Investor Presentation SvD Börsplus 11 Sept 2017
30 August, 2016 Swedencare AB (publ) – Interim Report (Q2 2016)
21 April, 2016 Swedencare AB (publ) – Company Presentation
Content

Årsstämma 2019

Årsstämma 2019

Legal Organization /
Board and Management.

Swedencare AB (publ)-Legal Organization

Swedencare

The parent company Swedencare AB (publ) is responsible for the strategy, business planning and management. This is done by the control of trademarks and patents, sales rights, cooperation agreements and as parent company of the subsidiaries. The Company and headquarter is located at Medeon Science Park in Malmö, Sweden.

Subsidiaries/Sales Company

Swedencare owns 100% of the shares to all subsidiaries/sales companies which are responsible for the sales and marketing for its individual regions. The subsidiaries provide a monthly financial report as well as a sales progress to Swedencare. The group also have a common ERP-system where orders and invoices are registered. The system enable an effective production planning at the same time as the subsidiaries can track the order progress. Through the local market knowledge of the subsidiaries the marketing can be customized and the local customer preferences and new products can easily and effectively be identified. The subsidiaries are located and managed in France, Great Britain, Ireland, Sweden and the US.

Board of Directors (BoD) and Management

The Board of Directors are responsible for the Company’s strategic and financial targets and, together with the management, for the strategic planning. In the BoD, there is an extensive experience of international sales and marketing as well as a wide international network. The Managing Director and CFO are responsible to provide a business plan in line with the BoDs strategic and financial targets. They are also responsible for financial planning, and questions and communication with the stock exchange. The CEO of the Company, together with the managing directors of the subsidiaries, is a management team responsible for product development as well as sales and marketing.

Board of Directors of Swedencare

Swedencare AB (publ)-Board-Members

Swedencare AB (publ)-Board-Member-Per-Malmstrom
Per Malmström
President of the Board since 2014 – Born 1961.

•  Background from the financial sector, among others SEB, Aragon Fondkommission, CFO at Adera AB 1998-2001 (Addnode AB), as well as several Board assignments. Bachelor of economics from Örebro Högskola.

•  Managing Director and member of the board at Per Malmström Consulting AB. President of the board in K3 Nordic AB, K3 Travel AB, SVANBERG & CO INVEST AB, Creative Tools, Northway Partners, Deligate AB.

Independent in relation to the company/company management: Yes
Independent in relation to the company’s major owners: No
Holding*:  123 000 shares

Swedencare AB (publ)-Board-Member-Hakan-Lagerberg
Håkan Lagerberg
Member of the board since 2014 – Born 1968.

•  International experience from leading positions in private and public companies. International Jur. Kand from Lunds University. Post graduate in International Trade Law from University of Torino in Italy.

•  Board member in all subsidiaries of Swedencare. President of the board in One CC AB. Member of the board in HAOLAG AB and Mastan AB. Deputy of the board in Cellares AB and Comera AB.

Independent in relation to the company/company management: No
Independent in relation to the company’s major owners: No
Holding*:  1 590 362 shares

Swedencare AB (publ)-Board-Member-Johan-Bergdahl
Johan Bergdahl
Member of the board since 2014 – Born 1970.

•  Entrepreneur and owner to several companies within sales, IT and property management. Degree in Market economy from Nercia Business School.

•  President of the board in Local Market Sweden AB and BR Group AB. Member of the board in Comera AB, JCC Group AB, JCC Group Invest AB, Junikvisten 10 AB, Rostastrand Holding AB, BR Group Holding AB, BR Group Fastigheter AB, Storgatan Fastigheter AB and Trygghandel AB.

Independent in relation to the company/company management: Yes
Independent in relation to the company’s major owners: No
Holding*:  1 552 351 shares

Swedencare AB (publ)-Board-Member-Tomas-Eklund
Thomas Eklund
Member of the board since 2016 – Born 1967.

•  Advisor to Impilo and former Managing Director of Investor Growth Capital in Europe. Extensive experience of investments and business development within the healthcare market.

•  President of the board in Biotage AB and Sedana Medical AB. Member of the board in Boule Diagnostics AB, Calliditas Therapeutics AB, Immedica Pharma AB, Rodebjer Form AB and Memira Holding AB.

Independent in relation to the company/company management: Yes
Independent in relation to the company’s major owners: Yes
Holding*:  190 000 shares

Swedencare AB (publ)-Board-Member-Hakan-Svanberg
Håkan Svanberg
Member of the board since 2014 – Born 1957.

•  Entrepreneur and owner to several companies within IT, travel and finance. Master in Philosophy from Örebro University.

•  Managing Director in SVANBERG & CO INVEST AB. Member of the board in Creative Tools, Deligate AB, EyeonID Group AB, K3 Nordic AB, SVANBERG & CO INVEST AB, H. Svanberg Software Holding, Northway Partners, Svanberg Factoring, Treberg Holding AB, Kontosmart AB. Deputy of the board in Chief Holding AB and SWG Holding AB.

Independent in relation to the company/company management: Yes
Independent in relation to the company’s major owners: No
Holding*:  4 690 982 shares

Swedencare AB (publ)-Board-Member-Sara-Brandt
Sara Brandt
Member of the board since 2019 – Born 1963.

•  Vice President Almi Företagspartner, former VP and CEO Berner Nordic and before that senior positions on ia. Cederroth Nordic, Coca-Cola Sweden, Unilever Nordic and UK. Long background from international B2C and B2B companies and broad experience from several industries and product categories such as consumer health and international distributor activities.
Board member of ClearOn and Almi Skåne.

Independent in relation to the company/company management: Yes
Independent in relation to the company’s major owners: Yes
Holding*:  –

Own or related holdings of shares and other financial instruments in Swedencare. Holding by June 30, 2019.

Management
hakan-lagerberg
Håkan Lagerberg
CEO – See above
jenny-graflind
Jenny Graflind
CFO

•  Jenny has been employed since 2017.

•  A long international background as CFO and previously as, among other functions Financial Controller and auditor of global groups, both privately owned as owned by private equity.
Bachelor of Science Management from Florida Atlantic University.

No other assignments.
Number of Shares in Swedencare:  40,000 stock options.

john-leonard
John Leonard
MD of subsidiaries Swedencare UK Ltd and Swedencare Ireland

•  John has been employed since 2012.

•  Over 20 years of experience from the Oralhealth industry as Sales Manager at TePe and Colgate and development manager at CTS dental.
HND Business & Finance from Teesside University.

No other assignments.
Number of Shares in Swedencare:  66,600 shares and 40,000 stock options.

hans-persson
Hans Persson
MD of the subsidiary SARL Buccosanté

•  Hans is employed since 2008.

•  Experience of international marketing, distribution and sales as well as 25 years of experience in leading smaller companies in the French market.
Engineering degree and degree in market economy from Lund.

No other assignments.
Number of Shares in Swedencare:  199,750 shares.

martin-shimko
Martin Shimko
MD of subsidiary SwedencareUSA Inc

•  Martin has been employed since 2005.

•  A background as management trainee from NASSCO and the management group in The Bohle Co.
Bachelor of Science in Engineering from the University of Michigan and a degree in accounting from the University of California LA.

No other assignments.
Number of Shares in Swedencare:  300 000 shares.

sabine-uhde
Sabine Uhde
Head of the Nordic subsidiary Swedencare Nordic AB

•  Sabine has been employed since 2015.

•  Background as department manager and from the marketing department on TT-line.
Associate Degree.

No other assignments.
Number of Shares in Swedencare:  10,000 stock options.

raquel-tosca
Raquel Tosca
Country Manager in the subsidiary Swedencare Spain SLU

•  Raquel has been employed since 2019.

•  An international background of international business, marketing and communication at the latest from the animal health company Laboratorios Calier. Master’s degree in Marketing, Communication & Digital Publicity from UOC University in Barcelona and Inesdi Digital Business School.

No other assignments.
Number of Shares in Swedencare:  -.

Articles of Association for
Swedencare AB (publ) (556470-3790)

§ 1 COMPANY NAME
The company name is Swedencare AB (publ). Public company.

§ 2 REGISTERED OFFICE
The registered head office of the company is in the municipality of Malmö.

§ 3 OBJECTS OF THE COMPANY
The company objective is, directly or indirectly, the development, manufacture and sale of products within the area of animal healthcare and preventive dental care and other business compatible therewith.

§ 4 SHARE CAPITAL
The share capital shall be not less than SEK 500,000 and not more than SEK 2,000,000.

§ 5 NUMBER OF SHARES
The number of shares shall be not less than 10,000,000 and not more than 40,000,000.

§ 6 FINANCIAL YEAR
The company’s financial year shall be calendar year.

§ 7 BOARD OF DIRECTORS
The board of directors shall consist of not less than three and not more than seven board members with not more than two deputy board members. The board members and deputy board members are elected annually for the period until the close of the first annual general meeting held after the year in which the board member or deputy board member was appointed.

§ 8 AUDITOR
For audit of the company’s annual report, the accounts and the administration of the board of directors and managing director, not less than one auditor and not more than two auditors with or without deputy auditors shall be elected.

§ 9 ANNUAL GENERAL MEETING

The following matters shall be addressed at the Annual General Meeting:

1. Election of a chairman at the meeting;

2. Preparation and approval of the voting list;

3. Election of one (1) or two (2) persons to verify the minutes of the meeting;

4. Approval of the agenda;

5. Determination of whether the meeting was duly convened;

6. Submission of the annual report and the auditor’s report, and if applicable, the group accounts and the auditor’s report for the group;

7. Resolutions:

(a) regarding the adoption of the income statement and balance sheet, and if applicable, the consolidated income statement and the consolidated balance sheet

(b) regarding allocation of profit or loss in accordance with the adopted balance sheet

(c) regarding the discharge from liability of the board members and, where applicable, of the managing director;

8. Determination of fees for the board of directors and, where applicable, for the auditors;

9. Election of the board of directors and auditors; and

10. Other matters which rest upon the meeting according to the Swedish Companies Act or the company’s articles of association.

§ 10 NOTICE TO ATTEND
Notice to attend a general meeting shall be advertised in Post- och Inrikes Tidningar (The Official Swedish Gazette) and on the company website. At the time of notice, information about the notice shall be advertised in Dagens Industri. The notice shall immediately, and at no cost for the recipient, be sent by post to those shareholders who so request and state their address.
Notice to attend an annual general meeting and notice to attend an extraordinary general meeting at which the issue of alterations of the articles of association is to be addressed shall be issued not earlier than six weeks and not later than four weeks prior to the meeting. Notice to attend an extraordinary general meeting other than such as mentioned above shall be issued not earlier than six weeks and not later than two weeks prior to the general meeting.

§ 11 APPLICATION IN ADVANCE
A shareholder, who wishes to participate at the general meeting, shall (i) be included in the transcript or other record of the share register as of five days before the meeting (ii) notify the company thereof not later than on the date specified in the notice to attend the general meeting. Such a date may not be a Sunday, other public holiday, Saturday, Midsummer Eve, Christmas Eve or New Year’s Eve and may not occur earlier than the fifth weekday prior to the general meeting. If the notice to attend the general meeting does not state a last day for notification, then notification is not required in order to participate at the general meeting. A shareholder who wishes to be accompanied by advisors at a general meeting shall state the number of advisors (not more than two) accompanying the shareholder in the application.

§ 12 CSD CLAUSE
The company’s shares shall be registered in a CSD (central securities depository) register in accordance with the Financial Instruments (Accounts) Act (1998:1479).

Articles of Association adopted at the general meeting held on March 7, 2016.

Swedencare AB (publ)
Press Releases

In the Press


August 6, 2019

Swedencare:
Highly rated and trendy

Animal health is a trendy subject on the stock exchange. The Swedish company Swedencare is one of the few Nordic investment alternatives on the international trend. Read more »


January 29, 2019

Swedencare’s flagship product ProDen PlaqueOff® Powder
has been awarded the VOHC® Seal of Acceptance

Two clinical studies* on dogs performed by Jerzy Gawor, DVM, PhD, DipAVDC/EVDC.
Read more »


Dec 5, 2018

Swedencare expanding its operations in Ireland

Swedencare AB announced today it has moved into new, larger premises in Waterford which it has redeveloped to more than double its capacity and expand its workforce presence in Waterford.
Read more »


October 1, 2018

Swedencare AB (publ)
launch new food co-op

with worldwide premium
dog food brand Canagan.
Read more »


May 18, 2018

Animal stock trade

– can be dubbed in the short term
Börslunch May 18
View video »


April 20, 2018

Remium’s analysis to institutions

Swedencare’s shares buy
benchmark set to 44 SEK
Read more »


April 4, 2018

Swedencare doubles manufacturing capacity

Malmö-based pet products firm Swedencare has acquired manufacturing and logistic premises in Ireland. Read more »


March 26, 2018

The pets are fine

The Pet Passion Index has hit the stock market. Read more »








Newsletter Sign-Up

Stay up-to-date with the latest investor related news, delivered right to your inbox!